rt-designs.com
Targeted Technology | Fund II - StemBioSys
http://www.rt-designs.com/portfolio.html
Fund II Fund I. Soluble Therapeutics, LLC. StemBioSys is a stem cell therapeutics development company using novel, patented cell matrix technology to provide proprietary stems cells for collaborative and in-house therapeutic solutions.
rt-designs.com
Targeted Technology | Home Page
http://www.rt-designs.com/index.html
The Targeted Technology Funds are focused on early stage investments in companies that we believe can advance ground breaking or disruptive technologies to significantly improve the practice of medicine and patient outcomes. We also favor technologies that can positively improve the efficiency, cost, or functionality of the development and manufacture of life science products.
t3dc.org
T3DC | Stakeholders
http://t3dc.org/t3dc/stakeholders-and-networks/stakeholders
The Texas Technology Development Center. The Texas Technology Development Center. T3DC Accelerator Description and Location. Previous Networking and Education Events. Map and Parcel Info. Texas Research and Technology Foundation. Texas Research and Technology Foundation. Alamo Colleges provide leadership in developing San Antonio’s assets and potential for innovation-led economic development through the delivery of technical assistance to entrepreneurs. City of San Antonio Economic Development Department.
rt-designs.com
Targeted Technology | Alan Dean
http://www.rt-designs.com/team.html
Alan Dean, MBA. Paul Castella, PhD, MBA. Catherine Burzik, MA. Gary Frashier, MBA, PE. Ian Clements, MSc. Jim Traa, MBA. Corey Levenson, PhD. Alan earned his MBA from the University of Alabama in Birmingham and his BS in Chemistry from the University of Alabama.
rt-designs.com
Targeted Technology | Press Releases 2014
http://www.rt-designs.com/press.html
Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more. ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more. DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more. ViroXis Corporation Achieves Key Clinical Milestones more.
SOCIAL ENGAGEMENT